Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00193245
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193466
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193440
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00193180
- Locations
- 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
🇺🇸Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193336
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00193050
Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT00193310
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193544